CELG - Celgene Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
78.37
-1.61 (-2.01%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close79.98
Open79.98
Bid78.35 x 1100
Ask78.37 x 800
Day's Range78.35 - 80.20
52 Week Range78.35 - 147.17
Volume6,790,127
Avg. Volume7,075,635
Market Cap56.923B
Beta1.31
PE Ratio (TTM)21.53
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • These Stocks Have Quadrupled in Just 1 Year
    Motley Fool20 hours ago

    These Stocks Have Quadrupled in Just 1 Year

    Find out how these companies have defied a choppy market.

  • 3 Top Biotech Stocks to Buy Right Now
    Motley Fool23 hours ago

    3 Top Biotech Stocks to Buy Right Now

    Want to invest in this promising industry but don't know where to start? Here are three stocks that can get the ball rolling.

  • FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs
    InvestorPlace2 days ago

    FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs

    The Food and Drug Administration (FDA) announced a shame list of companies that try to block generic drugs in order to ramp up profits.

  • Amgen Stock Rises over 2% on Drug Approvals
    Market Realist2 days ago

    Amgen Stock Rises over 2% on Drug Approvals

    On May 17, Amgen (AMGN) stock rose ~0.5% to the closing price of $174.65 per share following FDA approval of Aimovig. The company’s stock price has risen ~2.3% in the last week following recent drug approvals. Amgen’s stock price has risen ~11.2% over the last 12 months.

  • BlueBird Bio Stock Jumps over 6% on May 17
    Market Realist2 days ago

    BlueBird Bio Stock Jumps over 6% on May 17

    BlueBird Bio (BLUE) is a biotechnology company focused on developing gene therapy, cancer immunotherapy, and gene editing for the treatment of serious diseases. On May 17, Bluebird Bio (BLUE) stock jumped over 6.1% to the closing price of $189.30 per share, following positive news.

  • Jounce Therapeutics Gets Throttled, Loses 35% Today
    Motley Fool3 days ago

    Jounce Therapeutics Gets Throttled, Loses 35% Today

    The clinical-stage upstart reported disappointing news that sparked pessimism.

  • FDA names drugmakers accused of blocking cheaper generics
    Associated Press3 days ago

    FDA names drugmakers accused of blocking cheaper generics

    TRENTON, N.J. (AP) — U.S. drug regulators are publicizing information on brand-name drugmakers that use what government officials call "gaming tactics" to block cheaper copycat versions.

  • The FDA Is Trying To 'Shame' Celgene, Gilead — Here's Why It Won't Work
    Investor's Business Daily3 days ago

    The FDA Is Trying To 'Shame' Celgene, Gilead — Here's Why It Won't Work

    Celgene toppled to a four-year low Thursday after it appeared on a list from the FDA attempting to "shame" drugmakers working to block generic competition.

  • Reuters3 days ago

    FDA names drugmakers potentially acting to delay cheap generics

    The U.S. Food and Drug Administration on Thursday listed a number of drugmakers it said could be improperly blocking access to their medicines in order to delay generic competition. The FDA said the list contained all of the inquiries about drugs it had received from generic drugmakers since 2005. Releasing the list of drugmakers, which includes Celgene Corp, Johnson & Johnson, Gilead Sciences and Novartis AG, is part of the Trump administration's efforts to pressure companies to lower drug prices.

  • Nohla Therapeutics closes $45 million funding round to continue clinical trials
    American City Business Journals3 days ago

    Nohla Therapeutics closes $45 million funding round to continue clinical trials

    Nohla is a Fred Hutch spinout working to creat an "off the shelf" universal donor cellular therapy that doesn’t require the extremely close genetic matching of bone marrow.

  • The Punching Bag of Biotech Absorbs More Blows
    Bloomberg3 days ago

    The Punching Bag of Biotech Absorbs More Blows

    Celgene Corp., which is becoming one of Donald Trump’s biotech punching bags, just got a self-inflicted black eye. The company’s shares slid more than 1 percent after partner Jounce Therapeutics Inc. reported disappointing data late Wednesday for a cancer drug. Celgene teamed up with Jounce Therapeutics Inc. in 2016 to license a cancer treatment known as JTX-2011, agreeing to pay $225 million up front and as much as $2.6 billion in total for a drug that hadn’t yet been tested in humans.

  • The Wall Street Journal3 days ago

    [$$] Investors, Brace Yourselves for More Drug-Price Drama

    The next leg of the Trump administration’s plan to lower the cost of drug prices could get ugly for investors. As soon as Thursday the Food and Drug Administration plans to publish a database of complaint letters from generic drug companies to the agency alleging anticompetitive activities from branded pharmaceutical companies. It is likely that some complaints will pertain to high-price blockbuster drugs that investors watch most closely.

  • Bloomberg3 days ago

    U.S. Names Drugmakers ‘Gaming’ Safety System to Shield Profits

    The Trump administration released a list of pharmaceutical companies including Gilead Sciences Inc. and Celgene Corp. that rivals say are blocking attempts to create cheaper generic versions of their products. The move by the Food and Drug Administration is a major step by Commissioner Scott Gottlieb to end what he has called “gaming” of the system by branded drugmakers. The list, posted on the FDA website on Thursday, will be updated as generic manufacturers make the agency aware of further problems obtaining samples, he said.

  • U.S. Names Drugmakers ‘Gaming’ Safety System to Shield Profits
    Bloomberg3 days ago

    U.S. Names Drugmakers ‘Gaming’ Safety System to Shield Profits

    The Trump administration released a list of pharmaceutical companies including Gilead Sciences Inc. and Celgene Corp. that rivals say are blocking attempts to create cheaper generic versions of their products. The move by the Food and Drug Administration is a major step by Commissioner Scott Gottlieb to end what he has called “gaming” of the system by branded drugmakers. The list, posted on the FDA website on Thursday, will be updated as generic manufacturers make the agency aware of further problems obtaining samples, he said.

  • Gilead Sciences Stock: How Much Upside Do Analysts Expect?
    Market Realist4 days ago

    Gilead Sciences Stock: How Much Upside Do Analysts Expect?

    Gilead Sciences (GILD) is a research-based biopharmaceutical company focused on discovering, developing, and bringing to market innovative medicines for life-threatening diseases. Gilead released its first-quarter earnings on May 4. Of the 26 analysts covering Gilead Sciences stock in May, 16 of them have given the stock a “buy” or higher rating, and ten have given it a “hold.” The mean rating for the stock is 2.2 with a target price of $85.81, which implies an upside potential of 27.2% over its closing price of $66.99 on May 15.

  • Agilent Technologies: S&P 500’s Top Loss on May 15
    Market Realist4 days ago

    Agilent Technologies: S&P 500’s Top Loss on May 15

    The S&P 500’s top losses on May 15 were: Agilent Technologies (A) declined 9.7%. D.R. Horton (DHI) declined 6.7%. Lennar (LEN) declined 5.7%. Pultegroup (PHM) declined 5.4%. Celgene (CELG) declined 3.9%. Agilent Technologies

  • Investopedia4 days ago

    CRISPR Stocks Deserve a Second Look. Here's Why.

    Clustered Regularly Interspaced Short Palindromic Repeats, commonly known as CRISPR, the revolutionary gene editing method was first discovered by Francisco Monica in Spain, as a means to defend one’s body from invading viruses. To start with, let’s first focus on what exactly the gene editing process entails. Gene editing is primarily inserting, deleting or replacing DNA base pairs within a gene.

  • The Wall Street Journal5 days ago

    [$$] Nohla Therapeutics Collects $45 Million Series B to Treat Blood Diseases

    Nohla Therapeutics Inc., a Seattle-based developer of universal cellular therapies for blood diseases, has secured $45 million in Series B funding.

  • Benzinga5 days ago

    Analyst: Trump's 'Naming And Shaming' Campaign To Build Pharma Headline Risk

    The Food and Drug Administration announced Monday it would publish correspondence with drug manufacturers accused of abusing agency standards to foil generic competitors. Height Capital Markets considers the public censuring indicative of a broader federal strategy to pressure industry change. Harris expects President Donald Trump not to enforce aggressive policy but to use “the power of the bully pulpit” to spotlight offending companies and pressure pricing changes — a view seemingly vindicated by Health and Human Services Secretary Alex Azar.

  • MarketWatch5 days ago

    Your guide to the Trump drug price plan: who it affects and how

    President Donald Trump’s new plan, “American Patients First,” is supposed to make U.S. drug prices cheaper. For some players, there could be long-term concerns, including for pharmacy-benefit managers and other drug system middlemen. This was partly because many of the ideas in the plan had been raised by the Trump administration prior to the speech, including in a proposed 2019 budget.

  • How Much Upside Does Bristol-Myers Squibb Offer?
    Market Realist6 days ago

    How Much Upside Does Bristol-Myers Squibb Offer?

    Bristol-Myers Squibb (BMY) is a specialty biopharmaceutical company with operations on a global scale. Of the 22 analysts covering Bristol-Myers Squibb in May, nine of them have given the stock a “buy” or higher rating. Eleven have given it a “hold,” and two have given it a “sell.” The mean rating for the stock is 2.5 with a target price of $59.20, implying an upside potential of 16% over the stock’s closing price of $51.09 on May 9.

  • Analyzing Celgene’s Cash Flows in 1Q18
    Market Realist6 days ago

    Analyzing Celgene’s Cash Flows in 1Q18

    Celgene (CELG) spent $325.0 million in operating activities in 1Q18. In comparison, the company generated $853.0 million from operating activities in 1Q17. This $1.2 billion decrease was primarily attributable to the $1.1 billion initial payment made by the company for acquiring Impact Biosciences.

  • Better Buy: Ziopharm Oncology, Inc. vs. bluebird bio Inc.
    Motley Fool8 days ago

    Better Buy: Ziopharm Oncology, Inc. vs. bluebird bio Inc.

    Both clinical-stage biotechs have cutting-edge cancer therapies in their pipelines. But which stock wins in a head-to-head matchup?

  • TheStreet.com9 days ago

    Jim Cramer: I Don't Have a Catalyst for Celgene or Gilead

    After analyzing the biotech space, TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer doesn't have a catalyst for Celgene or Gilead.

  • MARKETS: Russell 2000 hits all-time high; Walmart earnings on deck; oil prices reverse; healthcare stocks in focus
    Yahoo Finance Video4 days ago

    MARKETS: Russell 2000 hits all-time high; Walmart earnings on deck; oil prices reverse; healthcare stocks in focus

    Yahoo Finance's Seana Smith on midday market action.